share_log

SVB Leerink Lowers Bluebird Bio (NASDAQ:BLUE) Price Target to $8.00

SVB Leerink Lowers Bluebird Bio (NASDAQ:BLUE) Price Target to $8.00

SVB 萊林克降低藍鳥生物(納斯達克:藍色)目標價格為 8.00 美元
kopsource ·  2023/01/27 16:08

bluebird bio (NASDAQ:BLUE – Get Rating) had its price target reduced by SVB Leerink from $9.00 to $8.00 in a research note issued to investors on Monday, Benzinga reports. They currently have a market perform rating on the biotechnology company's stock. SVB Leerink also issued estimates for bluebird bio's Q4 2022 earnings at ($1.18) EPS, FY2022 earnings at ($5.13) EPS, Q1 2023 earnings at ($0.64) EPS, Q2 2023 earnings at ($0.62) EPS, Q3 2023 earnings at ($0.58) EPS, Q4 2023 earnings at ($0.48) EPS, FY2023 earnings at ($2.31) EPS and FY2024 earnings at ($1.59) EPS.

據Benzinga報道,在週一發佈給投資者的一份研究報告中,SVB Leerink將藍鳥生物(納斯達克:Blue-Get評級)的目標價從9.00美元下調至8.00美元。他們目前對這家生物技術公司的股票進行了市場表現評級。SVB Leerink還發布了對藍鳥生物2022財年第四季度每股收益(1.18美元)、2022財年每股收益(5.13美元)、2023年第一季度每股收益(0.64美元)、2023年第二季度每股收益(0.62美元)、2023年第三季度每股收益(0.58美元)、2023年第四季度每股收益(0.48美元)、2023財年每股收益(2.31美元)和2024財年每股收益(1.59美元)的預期。

Several other equities analysts also recently weighed in on the company. Royal Bank of Canada lowered their target price on bluebird bio to $8.00 and set a sector perform rating on the stock in a research report on Tuesday, November 8th. StockNews.com began coverage on bluebird bio in a research report on Wednesday, October 12th. They issued a sell rating on the stock. Three analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of Hold and a consensus price target of $6.75.

其他幾位股票分析師最近也對該公司進行了分析。11月8日,加拿大皇家銀行在一份週二的研究報告中將藍鳥生物的目標價下調至8.00美元,並對該股設定了行業表現評級。StockNews.com在10月12日星期三的一份研究報告中開始報道藍鳥生物。他們對這隻股票發佈了賣出評級。三位分析師對該股的評級為賣出,六位分析師給出了持有評級,一位分析師給出了買入評級。根據MarketBeat的數據,該股目前的平均評級為持有,共識目標價為6.75美元。

Get
到達
bluebird bio
藍鳥傳記
alerts:
警報:

bluebird bio Stock Performance

藍鳥生物股票表現

NASDAQ BLUE opened at $6.23 on Monday. The company has a market capitalization of $516.61 million, a PE ratio of -1.02 and a beta of 0.99. The business's fifty day moving average is $7.36 and its 200 day moving average is $6.52. bluebird bio has a fifty-two week low of $2.87 and a fifty-two week high of $8.58.

納斯達克藍週一開盤報6.23美元。該公司市值為5.1661億美元,市盈率為-1.02,貝塔係數為0.99。該業務的50日移動均線切入位為7.36美元,200日移動均線切入位為6.52美元。藍鳥生物的52周低點為2.87美元,52周高位為8.58美元。

bluebird bio (NASDAQ:BLUE – Get Rating) last released its earnings results on Monday, November 7th. The biotechnology company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.28) by $0.36. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $2.25 million. bluebird bio had a negative return on equity of 173.58% and a negative net margin of 8,828.28%. On average, sell-side analysts forecast that bluebird bio will post -4.41 EPS for the current year.
青鳥生物(納斯達克:Blue-Get Rating)最近一次發佈財報是在11月7日(週一)。這家生物技術公司公佈了本季度每股收益(0.92美元),比普遍預期的(1.28美元)高出0.36美元。該公司本季度營收為70萬美元,而市場普遍預期為225萬美元。藍鳥生物的淨資產回報率為負173.58%,淨利潤率為負8,828.28%。賣方分析師平均預測,藍鳥生物今年的每股收益將達到4.41歐元。

Insider Transactions at bluebird bio

藍鳥生物的內幕交易

In other news, Director Nick Leschly sold 4,290 shares of bluebird bio stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $7.80, for a total value of $33,462.00. Following the sale, the director now directly owns 280,149 shares of the company's stock, valued at $2,185,162.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 9,506 shares of company stock valued at $72,088. 2.90% of the stock is currently owned by insiders.

其他新聞方面,董事尼克·萊施利在一筆日期為1月11日星期三的交易中出售了4,290股藍鳥生物股票。這隻股票的平均售價為7.8美元,總價值為33,462.00美元。交易完成後,董事現在直接持有280,149股阿里巴巴股票,價值2185,162.20美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可在美國證券交易委員會網站。在過去的三個月裏,內部人士已經出售了9,506股公司股票,價值72,088美元。該公司2.90%的股份目前由內部人士持有。

Institutional Investors Weigh In On bluebird bio

機構投資者參與藍鳥生物

Large investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY increased its stake in bluebird bio by 142.4% during the third quarter. Metropolitan Life Insurance Co NY now owns 4,671 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,744 shares during the last quarter. Amalgamated Bank bought a new stake in bluebird bio during the first quarter worth approximately $39,000. PEAK6 Investments LLC bought a new stake in bluebird bio during the second quarter worth approximately $41,000. US Bancorp DE grew its stake in shares of bluebird bio by 82.9% during the first quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company's stock valued at $41,000 after buying an additional 3,847 shares during the last quarter. Finally, Keybank National Association OH bought a new position in shares of bluebird bio during the second quarter valued at approximately $42,000. 79.01% of the stock is owned by institutional investors.

大型投資者最近對他們在該公司的頭寸進行了調整。紐約大都會人壽保險公司在第三季度增持了藍鳥生物的股份142.4%。紐約大都會人壽保險公司在上個季度增持了2,744股後,現在擁有4,671股這家生物技術公司的股票,價值30,000美元。合併銀行在第一季度購買了藍鳥生物的新股份,價值約3.9萬美元。Peak6 Investments LLC在第二季度購買了藍鳥生物的新股份,價值約41,000美元。US Bancorp DE在第一季度增持了藍鳥生物的股份82.9%。US Bancorp DE現在持有這家生物技術公司8486股股票,價值4.1萬美元,此前在上個季度又購買了3847股。最後,KeyBank National Association OH在第二季度購買了藍鳥生物的新頭寸,價值約42,000美元。79.01%的股票由機構投資者持有。

bluebird bio Company Profile

藍鳥生物公司簡介

(Get Rating)

(獲取評級)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

藍鳥生物公司是一家生物技術公司,研究、開發和商業化針對嚴重遺傳病的變革性基因療法。其用於治療嚴重遺傳性疾病的候選產品包括用於治療輸血依賴型β-地中海貧血的貝替貝吉基因Autotemcel;用於治療鐮狀細胞病(SCD)的lovotieglogene autemcel;以及用於治療大腦腎上腺腦白質營養不良的伊利伐多烯Autotemcel。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
  • The Future Of E-Commerce: Analysis And New Data
  • Chevron Delights Shareholders with $75 Billion in Share Buybacks
  • Levi Strauss Is A Good Fit For Income Investors
  • 3 Small Caps That Have Big Upside
  • Mullen Automotive: The Good News, The Bad And The Ugly Outlook
  • 免費獲取StockNews.com關於藍鳥生物的研究報告(藍色)
  • 電子商務的未來:分析和新數據
  • 雪佛龍以750億美元的股票回購取悦股東
  • 列維·施特勞斯非常適合收益型投資者
  • 3只小盤股有很大的上漲空間
  • 馬倫汽車:好消息、壞消息和醜陋的前景

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

獲得藍鳥生物日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對藍鳥生物和相關公司的最新新聞和分析師評級的每日簡明摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論